Upstream Bio, Inc. UPB
Set alert
3.49 USD +0.14 +4.18%
As of Nov 3, 9:49 AM ET
3.33 Day range 3.49
2.68 52-week range 33.68
- YTD
- -87.15%
- 1 year
- -86.05%
- Open
- 3.36
- Prev close
- 3.35
- Mkt cap
- 191.15M
- Vol
- 142.04K
- Avg vol
- 858.97K
- EPS
- -2.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.33
- High
- 3.49
- Forward P/E
- -2.45
- Beta
- 0.00
- Short ratio
- 2.45
- Inst. own
- 94.73%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.55
- 200-d avg
- 19.11
- 1y target
- 47.86
6M chart
Signals (26)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 6 days ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 5, 2026 | 4 weeks ago |
| RSI: Oversold | Oct 5, 2026 | 4 weeks ago |
| MACD: Buy Signal | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 5, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 21, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| RSI: Oversold | Jun 10, 2026 | 4 months ago |
| RSI: Oversold | Jun 8, 2026 | 4 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
Newest 20 of 26.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.86 +1271.3% upside
Now 3.49
- Target (low)
- 35.00
- Target (mean)
- 47.86
- Target (high)
- 75.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 8
- 2 months ago 8
- 3 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.76667 | -0.79 – -0.74 | -0.51 | -50.3% | 604.00K | +6.7% | 3 |
| Next quarter | -0.71 | -0.75 – -0.69 | -0.74 | +4.0% | 606.50K | -35.3% | 3 |
| Current year | -2.82 | -2.89 – -2.75 | -2.66 | -5.9% | 1.21M | -57.7% | 3 |
| Next year | -3.52 | -5.33 – -2.07 | -2.82 | -24.9% | 1.22M | +0.8% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Dec 18, 2025 | Mizuho | Initiated | — | Outperform |
| Dec 2, 2025 | LifeSci Capital | Initiated | — | Outperform |
| Nov 18, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Oct 14, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 5, 2024 | JP Morgan | Initiated | — | Overweight |
| Nov 5, 2024 | William Blair | Initiated | — | Outperform |
| Nov 5, 2024 | TD Cowen | Initiated | — | Buy |
| Nov 5, 2024 | Piper Sandler | Initiated | — | Overweight |